ACT Brief: Protocol Design as Business Strategy, Site Financial Pressures, and FDA Leadership Uncertainty

In today's ACT Brief, we examine how protocol design decisions have become strategic business choices with outsized consequences for smaller companies, what clinical research sites need to compete and deliver, and leadership changes at the FDA.